Cart
sales@molnova.com
CAY-10603
CAS No. 1045792-66-2
CAY-10603( CAY10603 )
Catalog No. M10225 CAS No. 1045792-66-2
A highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 68 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 156 | In Stock |
|
| 25MG | 291 | In Stock |
|
| 50MG | 492 | In Stock |
|
| 100MG | 709 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCAY-10603
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent and selective HDAC6 inhibitor with IC50 of 2 pM.
-
DescriptionA highly potent and selective HDAC6 inhibitor with IC50 of 2 pM; 200-fold less potent for HDAC3 (IC50=0.42 nM) and no inhibition on HDAC1/2/8/10 (IC50> 100 nM); downregulates the levels of EGFR protein and synergizes with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines.(In Vitro):CAY10603 (Compound 7) shows potent inhibitory activities against pancreatic cancer cell lines, with IC50s of 1, 0.3, 0.1, 0.1, 0.6, <1, 0.5 μM for BxPC-3, HupT3, Mia Paca-2, Panc 04.03, SU.86.86, HMEC, HPDE6c7, respectively. CAY10603 (100 nM, 200-300 nM) is active against both the Mia Paca-2 and Panc04.03 cell lines. CAY10603 inhibits HDAC6 deacetylase activity, and supresses the proliferation of lung adenocarcinoma cells. CAY10603 also induces apoptosis of lung adenocarcinoma cells. Furthermore, CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway.
-
In VitroCAY10603 (Compound 7) shows potent inhibitory activities against pancreatic cancer cell lines, with IC50s of 1, 0.3, 0.1, 0.1, 0.6, <1, 0.5 μM for BxPC-3, HupT3, Mia Paca-2, Panc 04.03, SU.86.86, HMEC, HPDE6c7, respectively. CAY10603 (100 nM, 200-300 nM) is active against both the Mia Paca-2 and Panc04.03 cell lines. CAY10603 inhibits HDAC6 deacetylase activity, and supresses the proliferation of lung adenocarcinoma cells. CAY10603 also induces apoptosis of lung adenocarcinoma cells. Furthermore, CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway.
-
In Vivo——
-
SynonymsCAY10603
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC1|HDAC6
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1045792-66-2
-
Formula Weight446.4968
-
Molecular FormulaC22H30N4O6
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(OC(C)(C)C)NC1=CC=C(C2=CC(C(NCCCCCCC(NO)=O)=O)=NO2)C=C1
-
Chemical NameCarbamic acid, N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]carbonyl]-5-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kozikowski AP, et al. J Med Chem. 2008 Aug 14;51(15):4370-3.
2. Wang Z, et al. Oncol Rep. 2016 Jul;36(1):589-97.
molnova catalog
related products
-
TYA-018
TYA-018 is an orally available and selective HDAC6 inhibitor with cardioprotective properties for the study of dilated heart disease and heart failure.TYA-018 prevents sarcomere damage and decreases Nppb expression.
-
HDAC6 inhibitor NCT-...
A potent, selective HDAC6 inhibitor with IC50 of 84 nM, with IC50s of >3.5 uM for the other HDAC isoforms.
-
TMP-195
A first-in-class, potent, selective class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) inhibtior with IC50 of 60, 59, 26, and 15 nM, respectively.
